Foreign media reported that since the beginning of August, we have been concerned about the outbreak of lung damage associated with the use of e-cigarettes. On September 19, 2019, the U.S. Food and Drug Administration (FDA) opened a criminal investigation into an outbreak of lung damage associated with e-cigarettes, and the U.S. Centers for Disease Control and Prevention (CDC) at the time identified 530 cases – a number that has increased significantly since then.
Back in August, the Wisconsin Department of Health issued a statement warning that “severe lung disease” could be linked to the use of e-cigarette devices. On August 9, the Illinois Department of Health issued a similar statement – and on August 13, Minnesota issued another statement.
On September 6, the CDC reported a third fatality associated with lung disease caused by the use of e-cigarettes. At the time, they reported more than 450 cases of severe lung disease from 33 u.S. states. By October 10, there were nearly 1,200 cases of lung damage in the United States, with more than 22 deaths.
On October 14, the CDC officially named the e-cigarette-related lung loss disease EVALI and provided an accurate case number. Since then, the CDC has announced that the number of cases of serious lung disease related to e-cigarettes or e-cigarette products has risen to 2,172 (as of November 13, 2019).
These cases come from 49 states (except Alaska), the District of Columbia and two U.S. overseas dependencies (Puerto Rico and the U.S. Virgin Islands). As of November 13, 2019, 42 deaths have been confirmed in 24 states and the District of Columbia.
As of October 15, 2019, CDC data showed that 867 patients received information about substances used in e-cigarette products in the three months prior to the onset of symptoms. Of these patients, about 86 percent reported using products containing tetrahydrocannabinol (THC); Some 64 per cent reported that nicotine-containing products were used;